Tixagevimab/AZD8895 represents a distinct therapeutic approach utilizing dual monoclonal antibodies. Specifically, these compounds work by precisely attaching to the receptor-binding domain of the SARS-CoV-2 agent, https://www.targetmol.com/compound/tixagevimab